GlassScriptPhysician profile
Jonathan Parks Gardner
NPI 1992904528
$5,760.80
in general payments reported to CMS, 2019-2025
20 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $181 · 2021: $761 · 2022: $2,085 · 2023: $1,780 · 2024: $589 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,444 · Travel and Lodging: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.10 |
| Travel and Lodging | $289.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,043.75 | 2021-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, General - Pain Management |
| Curonix LLC | $675.33 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spinal Simplicity, LLC | $609.81 | 2022-2024 | Ha Minuteman G3-R |
| Nevro Corp. | $245.68 | 2021-2024 | Senza |
| Medtronic, INC. | $195.43 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Abbott Laboratories | $183.46 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Avanos Medical | $181.48 | 2020 | |
| Si-Bone, INC. | $119.53 | 2022-2023 | |
| Painteq LLC | $110.20 | 2023-2024 | Painteq |
| Collegium Pharmaceutical, INC. | $79.51 | 2024-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.54 | 2024-2025 | Relistor |
| Kowa Pharmaceuticals America, INC. | $52.14 | 2022-2023 | Seglentis |
| Depuy Synthes Sales INC. | $42.75 | 2022-2023 | Velys |
| Eagle Pharmaceuticals, INC. | $34.69 | 2023-2024 | |
| Globus Medical, INC. | $24.31 | 2025 | Vyrsa V1 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.53 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $22.30 | 2024 | |
| Virtus Pharmaceuticals LLC | $16.32 | 2021 | |
| Abbvie INC. | $15.31 | 2021 | |
| Biodelivery Sciences International, INC. | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.